ArticleClinicoEconomics and outcomes research : CEOR2026
Real-World Treatment Patterns of Elranatamab in Patients with Multiple Myeloma in Japan: The EVEREST Study.
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Elranatamab, a B-cell maturation antigen-CD3 bispecific antibody, was approved in Japan in March 2024 for the treatment of relapsed or refractory multiple myeloma (MM). However, real-world (RW) data on its use remain limited. This retrospective study evaluated patient characteristics and elranatamab treatment patterns in patients with MM in Japan using the Medical Data Vision (MDV) database. Methods: This EVEREST study used de-identified claims data from the MDV database for adult patients with MM who initiated treatment with elranatamab between March 26, 2024, and March 31, 2025. Follow-up was divided, based on expected dosing schedules, into a step-up dosing (SUD) period, a weekly (QW) maintenance period (MP1), an every 2 weeks (Q2W) maintenance period (MP2), and an overall follow-up period. Treatment patterns were reported descriptively. Estimated annual vial usage was extrapolated. Results: Patients (N=253) with a median age of 74 years (range 41-93 years) and median treatment duration of 60.0 days (interquartile range [IQR], 26.0-136.0) were included. The mean (median [IQR]) time between elranatamab administrations across dosing periods were SUD 4.0 days (4.0 [3-4]), MP1 9.8 days (7.0 [7-9]), and MP2 13.0 days (14.0 [7-14]), indicating less frequent dosing than recommended in MP1, and comparable dosing in MP2. Nearly all administrations were in inpatient settings during SUD, and most were in outpatient settings during maintenance periods. Despite variable dosing during the maintenance periods, annual elranatamab usage was lower than the approved label recommendations for Japan (34.4 vs 39.0 vials per year). Conclusion: Early RW data on elranatamab administration and vial usage in patients with MM in Japan suggest that dosing is generally aligned with label expectations, with variable dosing during QW and Q2W maintenance for some patients. Projected vial usage in this RW setting was lower than the expected usage per label.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.